For obstructive sleep apnoea (OSA), few mechanical treatment options are available and no pharmacotherapy is approve]. However, safe and efficacious pharmacotherapy would have substantial appeal for many people with OSA.
A promising target is pharmacological treatment increasing upper airway stability by activating the genioglossus muscle. Its activation by the central respiratory control system is importantly modified by mechanoreceptive reflex mechanisms operating locally in the upper airways and modulated by changes in pharyngeal pressure . It has been shown that genioglossus muscle activity and reflex modulation to changes in airway pressure are sleep stage dependent. Many OSA patients have apnoea-free intervals in which genioglossus muscle activity is only 25–40% higher compared with sleep phases with frequent obstructive apnoeas...
- obstructive sleep apnoea
- BAY 2253651
- Patient outcomes